Your browser doesn't support javascript.
loading
Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6.
Vance, Caroline; Rogelj, Boris; Hortobágyi, Tibor; De Vos, Kurt J; Nishimura, Agnes Lumi; Sreedharan, Jemeen; Hu, Xun; Smith, Bradley; Ruddy, Deborah; Wright, Paul; Ganesalingam, Jeban; Williams, Kelly L; Tripathi, Vineeta; Al-Saraj, Safa; Al-Chalabi, Ammar; Leigh, P Nigel; Blair, Ian P; Nicholson, Garth; de Belleroche, Jackie; Gallo, Jean-Marc; Miller, Christopher C; Shaw, Christopher E.
Afiliación
  • Vance C; Department of Clinical Neuroscience, King's College London, Medical Research Council (MRC) Centre for Neurodegeneration Research, Institute of Psychiatry, London SE5 8AF, UK.
  • Rogelj B; Department of Clinical Neuroscience, King's College London, Medical Research Council (MRC) Centre for Neurodegeneration Research, Institute of Psychiatry, London SE5 8AF, UK.
  • Hortobágyi T; Department of Clinical Neuroscience, King's College London, Medical Research Council (MRC) Centre for Neurodegeneration Research, Institute of Psychiatry, London SE5 8AF, UK.
  • De Vos KJ; Department of Neuroscience, King's College London, MRC Centre for Neurodegeneration Research, Institute of Psychiatry, London SE5 8AF, UK.
  • Nishimura AL; Department of Clinical Neuroscience, King's College London, Medical Research Council (MRC) Centre for Neurodegeneration Research, Institute of Psychiatry, London SE5 8AF, UK.
  • Sreedharan J; Department of Clinical Neuroscience, King's College London, Medical Research Council (MRC) Centre for Neurodegeneration Research, Institute of Psychiatry, London SE5 8AF, UK.
  • Hu X; Department of Clinical Neuroscience, King's College London, Medical Research Council (MRC) Centre for Neurodegeneration Research, Institute of Psychiatry, London SE5 8AF, UK.
  • Smith B; Department of Clinical Neuroscience, King's College London, Medical Research Council (MRC) Centre for Neurodegeneration Research, Institute of Psychiatry, London SE5 8AF, UK.
  • Ruddy D; Department of Clinical Neuroscience, King's College London, Medical Research Council (MRC) Centre for Neurodegeneration Research, Institute of Psychiatry, London SE5 8AF, UK.
  • Wright P; Department of Clinical Neuroscience, King's College London, Medical Research Council (MRC) Centre for Neurodegeneration Research, Institute of Psychiatry, London SE5 8AF, UK.
  • Ganesalingam J; Department of Clinical Neuroscience, King's College London, Medical Research Council (MRC) Centre for Neurodegeneration Research, Institute of Psychiatry, London SE5 8AF, UK.
  • Williams KL; Northcott Neuroscience Laboratory, Australian and New Zealand Army Corps (ANZAC) Research Institute, Concord, NSW 2139, Australia.
  • Tripathi V; Department of Clinical Neuroscience, King's College London, Medical Research Council (MRC) Centre for Neurodegeneration Research, Institute of Psychiatry, London SE5 8AF, UK.
  • Al-Saraj S; Department of Clinical Neuroscience, King's College London, Medical Research Council (MRC) Centre for Neurodegeneration Research, Institute of Psychiatry, London SE5 8AF, UK.
  • Al-Chalabi A; Department of Clinical Neuroscience, King's College London, Medical Research Council (MRC) Centre for Neurodegeneration Research, Institute of Psychiatry, London SE5 8AF, UK.
  • Leigh PN; Department of Clinical Neuroscience, King's College London, Medical Research Council (MRC) Centre for Neurodegeneration Research, Institute of Psychiatry, London SE5 8AF, UK.
  • Blair IP; Northcott Neuroscience Laboratory, Australian and New Zealand Army Corps (ANZAC) Research Institute, Concord, NSW 2139, Australia.
  • Nicholson G; Faculty of Medicine, University of Sydney, Sydney, NSW 2139, Australia.
  • de Belleroche J; Northcott Neuroscience Laboratory, Australian and New Zealand Army Corps (ANZAC) Research Institute, Concord, NSW 2139, Australia.
  • Gallo JM; Molecular Medicine Laboratory, Concord Hospital, Concord, NSW 2139, Australia.
  • Miller CC; Faculty of Medicine, University of Sydney, Sydney, NSW 2139, Australia.
  • Shaw CE; Division of Neurosciences and Mental Health, Faculty of Medicine, Imperial College London, Hammersmith Hospital, London W12 0NN, UK.
Science ; 323(5918): 1208-1211, 2009 Feb 27.
Article en En | MEDLINE | ID: mdl-19251628
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that is familial in 10% of cases. We have identified a missense mutation in the gene encoding fused in sarcoma (FUS) in a British kindred, linked to ALS6. In a survey of 197 familial ALS index cases, we identified two further missense mutations in eight families. Postmortem analysis of three cases with FUS mutations showed FUS-immunoreactive cytoplasmic inclusions and predominantly lower motor neuron degeneration. Cellular expression studies revealed aberrant localization of mutant FUS protein. FUS is involved in the regulation of transcription and RNA splicing and transport, and it has functional homology to another ALS gene, TARDBP, which suggests that a common mechanism may underlie motor neuron degeneration.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Mutación Missense / Proteína FUS de Unión a ARN / Esclerosis Amiotrófica Lateral Límite: Animals / Female / Humans / Male Idioma: En Revista: Science Año: 2009 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Mutación Missense / Proteína FUS de Unión a ARN / Esclerosis Amiotrófica Lateral Límite: Animals / Female / Humans / Male Idioma: En Revista: Science Año: 2009 Tipo del documento: Article